Lataa...
ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
With the advent of new agents targeting CD20, Bruton’s tyrosine kinase, and phosphoinositol-3 kinase for chronic lymphoid leukemia (CLL), more treatment options exist than ever before. B-cell lymphoma-2 (BCL-2) plays a major role in cellular apoptosis and is a druggable target. Small molecule inhibi...
Tallennettuna:
| Julkaisussa: | J Hematol Oncol |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
BioMed Central
2015
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4654800/ https://ncbi.nlm.nih.gov/pubmed/26589495 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-015-0224-3 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|